BioInvent International AB (publ)
BioInvent International AB (publ) (BOVNF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bovnf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for BioInvent International AB (publ) (BOVNF) measures how much investors pay for each dollar of the company's trailing earnings. BOVNF's current PE ratio of N/A is calculated by dividing its stock price of $6.63 by its TTM earnings per share of -$5.09.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
BioInvent International AB (publ)You BOVNF | $436M | N/A | — | -$5.09 |
 Avacta Group Plc AVCTF | $437M | N/A | — | -$0.10 |
 Clinuvel Pharmaceuticals Limited CLVLY | $339M | 14.30x | -76.8% | $0.72 |
 CytoDyn Inc. CYDY | $409M | 109.11x | +76.8% | $0.00 |
 GenSight Biologics S.A. GSGTF | $31M | N/A | — | -$0.08 |
 Healios K.K. HLOSF | $291M | N/A | — | -$20.61 |
 MedinCell S.A. MDCLF | $1.2B | N/A | — | -$0.63 |
Industry Average 2 peers with valid PE | — | 61.71x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-5.05 | — | |
2024-12-31 FY2024 | — | $-6.53 | — | |
2023-12-31 FY2023 | — | $-5.02 | — | |
2022-12-31 FY2022 | — | $-0.55 | — | |
2021-12-31 FY2021 | — | $-5.15 | — | |
2020-12-31 FY2020 | — | $-2.67 | — | |
2019-12-31 FY2019 | — | $-7.53 | — | |
2018-12-31 FY2018 | — | $-9.07 | — | |
2017-12-31 FY2017 | — | $-8.08 | — | |
2016-12-31 FY2016 | — | $-6.18 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for BioInvent International AB (publ) (BOVNF) measures how much investors pay for each dollar of the company's trailing earnings. BOVNF's current PE ratio of N/A is calculated by dividing its stock price of $6.63 by its TTM earnings per share of -$5.09.
Frequently asked questions
BOVNF pe ratio · 6 questionsBOVNF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $6.63 and TTM EPS of -$5.09. Data sourced from Financial Modeling Prep via BOVNF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · BioInvent International AB (publ) SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09